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Many patients with immune thrombocytopenia (ITP) may require special attention and long-
term treatment. Little is known on the efficacy and tolerability of the drugs used in practice.
Material and methods
We retrospectively reviewed the results of therapy of 400 patients with chronic ITP. All
Patients were treated at our institution between 1996–2016 under consideration of guide-
lines, general recommendations, and individual aspects, including gender, age, weight,
comorbidity, patient’s medical history and bleeding risk.
Results
Treatment was not required in 25% of patients (n = 100) during observation. In treated
patients (n = 300), the rate of patients that responded and tolerated treatment with predniso-
lone was 59% (52/88), with azathioprine 32% (29/90), with eltrombopag 49% (31/63), with
romiplostim 59% 27/45, with IVIG (intravenous immunoglobulines) 75% (94/126), with anti-
D 37% (19/52) and with dexamethasone 60% (25/42) patients. Eighteen treated patients
(6%) entered sustained remission after treatment with various drugs. Twenty-six patients
underwent splenectomy (Splx) resulting in sustained remission in 15 cases (60%). Only two
patients remained refractory to Splx and to all used drugs.
Discussion
None of the currently available drugs used in the treatment of ITP are invariably safe and
effective. Responses, the duration of response, intolerability, and the course of disease are
unpredictable. Although the treatment of ITP has considerably improved in the recent years,
the currently available drugs may rarely cure affected patients. The need for safe and effec-
tive therapy in ITP is evident. Optimal treatment decisions for each patient remains a chal-
lenge in many cases.
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Introduction
Almost 100 years have passed since the establishment of splenectomy (Splx) as the first and still
successfully used therapeutic measure in management of immune thrombocytopenia (ITP) [1].
The second therapeutic measure available for ITP patients was cortisone, which became avail-
able in 1951 [2], and was later on replaced by modified and less toxic steroids [3]. Since the
1960’s, immunosuppressive drugs including azathioprine, cyclophosphamide, vincristine and
vinblastine have been used, but their use remains limited in ITP [4]. A new era in the treatment
of ITP was established in 1981 with the observation that intravenous immunoglobulins (IVIG)
resulted in an unexpected increase in platelet counts (plc) in children with ITP [5, 6]. Soon
thereafter, a fourth alternative was incorporated into the list of therapeutic options in ITP: anti-
D [7]. The late 1990s saw the introduction of rituximab [8], whereas the turn of the new century
was influenced by well-designed studies using thrombopoietin receptor agonists (TPO-RA) [9–
12]. Although the list of available drugs in the treatment of ITP is growing, there remain several
unsatisfactory aspects [13]. These include the results and comments of several reviews and
reports dealing with ITP management and outcomes [4, 14–22] and various guidelines on the
management of ITP [23–26]. The recommendations are somewhat arbitrary and cannot be
applied in many cases [14, 18, 26–29]. In addition, many factors including ethnicity [30, 31],
subjective opinion, and conflict of interest may play a role in the management of ITP. Ulti-
mately, there is no specific curative treatment for autoimmune diseases. The present study
focuses on the long-term efficacy and safety of drugs used in the treatment of patients with ITP
in our institute during the last two decades. The results clearly indicate that the treatment of
ITP has improved, but still should be replaced by more specific and safe drugs.
Materials and methods
Data from 400 patients (398 adults, and 2 children; 143 males and 257 females) with a mean age
of 50.5 years (range, 3–101 years) that were diagnosed with chronic ITP [32], between 1964 and
2015 were retrospectively reviewed and analyzed to assess the efficacy and safety of the used ther-
apies. All patients were treated on an outpatient basis at our institution by a single physician
between 1996 and 2016. Standard dose of therapeutic agents was used (Prednisolone 0,5–1 mg/
kg/d for 1–3 weeks, 7,5 mg/d for>3 weeks; Dexamethasone 40 mg/d for 4 days (1–6 cycles
every 14–28 days); IVIG 0,4–2 g/kg; Anti-D 50–75 μg/kg; Rituximab 375 mg/m2/week for 4
times; Splx laparoscopic; Azathioprine 1-2mg/kg/d; Eltrombopag 50–75 mg/d; Romiplostim
1–10 μg/kg/week; Dapsone 75–100 mg/d; Cyclophosphamide 1–2 mg/kg/d p.o., 0,3–1 g/m2 i.v.
every 2–4 weeks; Ciclosporine A 5 mg/kg/d for 6 days then 2,5–3 mg/kg/d (titration to 100–200
ng/ml blood level); Mycophenolate-mofetil 1000–2000 mg/d; MTX 5–25 mg/week) [22–24]. In
short-course treatments (Table 1) (e.g., IVIG, dexamethasone, anti-D, rituximab, Splx), response
was defined as an elevation of plc 30 x 109/L with at least doubling of the baseline value within
their individual agent/intervention time to peak response [32]. In patients under continuous
treatments (Table 2), response criteria were a sustained elevation of plc 30 x 109/L with at least
doubling of the baseline value and compensated primary hemostasis during treatment observa-
tion. Sustained remission was defined as plc 100 x 109/L without the requirement of further
ITP therapy during at least 3 months of further observation (mean 25, months/range 3–108
months). Prior to assessment, all data has been fully anonymized. This study was approved by
the institutional ethics review board (EA2/058112) of the Charite´, Universita¨tsmedizin Berlin.
Results
Prior to consultation at our institution, 257 of 400 patients underwent treatment with therapies
that were ineffective and/or intolerable due to side effects (Fig 1). The mean number of
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previous therapies was two (range 1–6). Prednisolone was the most frequent previously used
drug (84%). The vast majority of these patients (88%) discontinued prednisolone due to ineffi-
cacy and/or intolerability including weight gain, hypertension, diabetes, osteoporosis, gastric
ulceration or depression, resulting in a switch in therapy prior to initial consultation at our
institution (Fig 1).
Table 1. Results of short-course treatments in patients with ITP during observation at our institution (n = 190).
Therapy Patients (n) Response Non-R Total ARs Cycles in R-patients (mean/range)
Total Documented Total R Intolerability/R SR/R
IVIG 133 126 94 (75%) - 4/94 32 (25%) 18 (14%) 3.1/1–25
Anti-Da 54 52 19 (37%) - - 33 (63%) 2 (4%) 3.8/1–19
Dexa 44 42 25 (60%) 1/25 - 17 (40%) 4 (10%) 1.3/1–4
Rituxi 4 4 1 (25%) - - 3 (75%) - 1.5/1–3
Splx 26 25 - - 15 (60%) 10 (40%) 1 (4%) -
R = response (elevation of platelets 30 x109/L and at least doubling of the baseline value within their known agent specific time to peak response [32]).
SR = sustained remission (sustained platelet count100 x 109/L without any further ITP therapy during at least 3 months of further observation).
Non-R = non-responder (patients that did not show elevation of platelets 30 x109/L and at least doubling of the baseline value)
ARs = adverse reactions
Documented = patients with available follow-up data
Dexa = dexamethasone, IVIG = intravenous immunoglobuline, Rituxi = rituximab, Splx = splenectomy
a One patient with Splx prior to anti-D treatment
https://doi.org/10.1371/journal.pone.0198184.t001
Table 2. Results of continuous treatments in patients with ITP during observation at our institution (n = 234).
Therapy Patients (n) Response Non-R Total ARs Treatment time in months (mean/range)
Total Documented Total R Intolerability/R SR/R
Pred 92 88 64 (73%) 12/64 8/64 24 (27%) 30 (34%) 21.2 / 1–210
Aza 14 12 7 (58%) 1/7 1/7 5 (42%) 4 (33%) 13.6/0.5–48
Aza + Pred 82 78 42 (54%) 19/42 1/42 36 (46%) 34 (44%) 15/0.5–108
Romip (+Preda) 52 45 35 (78%) 8/35 - 10 (22%) 15 (33%) 12,1/0.75–72
Eltromb 64 63 45 (71%) 14/45 4/45 18 (29%) 22 (35%) 15.6/0.5–96
MTX (+Predb) 5 5 2 (40%) - - 3 (60%) - 48.2/2–175
Cycl (+Predc) 6 6 4 (66%) - - 2 (33%) 2 (33%) 13.3/1.5–29
Ciclo (+Predd) 12 10 1 (10%) - - 9 (90%) 1 (10%) 5.8/0.75–18
MMF (+Prede) 15 14 7 (50%) 3/7 - 7 (50%) 6 (43%) 15.7/ 1–60
Dapsone 3 3 1 (33%) - - 2 (66%) - 41.3/ 2–120
R = response (sustained platelet counts30 x109/L with at least doubling the baseline value and absence of bleeding during observation).
SR = sustained remission (sustained platelet counts100 x 109/L without any further ITP therapy during at least 3 months of further observation).
Non-R = non-responder (patients that did not show elevation of platelets 30 x109/L and at least doubling of the baseline value).
ARs = adverse reactions
Documented = patients with available follow-up data
Aza = azathioprine, Ciclo = ciclosporine, Cycl = cyclophosphamide, Eltromb = eltrombopag, MMF = mycophenolate- mofetil, MTX = methotrexate,
Pred = prednisolone, Romip = romiplostim
a Five patients with concomitant prednisolone therapy;
b four patients with concomitant prednisolone therapy;
c five patients with concomitant prednisolone therapy;
d one patient with concomitant prednisolone therapy;
e twelve patients with concomitant prednisolone therapy
https://doi.org/10.1371/journal.pone.0198184.t002
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One hundred (25%), including the two children, of the 400 patients did not require any
therapeutic intervention during observation due to mild ITP and the absence of any bleeding
and/or high bleeding risks. Of these 100 patients, 32 (39%) entered remission, 51 patients
(61%) had persistent, but still mild ITP without the need for therapy, and long-term follow-up
was absent in 17 patients (Fig 2).
Fig 1. Patient and clinical characteristics.
https://doi.org/10.1371/journal.pone.0198184.g001
Fig 2. Patients that just required controls due to mild ITP without any therapy during observation.
https://doi.org/10.1371/journal.pone.0198184.g002
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The remaining 300 patients received an average of two treatments (range 1–10) during
observation at our institute.
A total of 92 patients (23%) received prednisolone for at least one month (Table 2). Follow-
up data were not available in four cases (4%). In the remaining 88 patients, 64 (73%)
responded to this treatment. However, only eight (13%) of the responding patients entered
sustained remission. Despite low-dose therapy (1–7.5 mg/d; Table 2), 12 (19%) patients devel-
oped intolerability during observation. Twenty-four patients (27%) did not respond to
treatment.
Azathioprine was used in 96 patients (24%), 82 of those had additional concomitant treat-
ment with low-dose prednisolone (1–7.5 mg/d; Table 2). Six patients (6%) were not evaluated
due to lack of follow-up data. In the remaining 90 patients, 49 patients (54%) responded to the
treatment and 20 (41%) of those patients discontinued therapy due to adverse reactions, which
included diverse gastrointestinal symptoms, hair loss, and drug fever. Two patients (2%)
entered sustained remission without the need for further ITP therapy. Forty-one patients
(46%) did not respond to the drug.
Forty-four patients (11%) were treated with dexamethasone at least once during observa-
tion (Table 1). Two patients (5%) were not evaluated due to lack of follow-up data. Of the
remaining 42 patients, 25 (60%) responded to treatment (Table 1). Adverse reactions (head-
ache, insomnia, mood disturbances, agitation, anxiety) were observed irregularly, and were
tolerable in most cases. Seventeen patients (40%) did not respond to dexamethasone.
Other immunosuppressive drugs including, cyclophosphamide, ciclosporin, mycopheno-
late- mofetil and rituximab showed response rates ranging from 10 to 66% (Tables 1 and 2). In
addition, combination therapy with the aforementioned drugs and concomitant prednisolone
therapy ( 7,5 mg/d) was used in some patients (Table 2). Adverse reactions observed during
treatment with immunosuppressive drugs were largely in agreement with previously reported
data [22–25].
Fifty-two patients (13%) were treated with romiplostim (Table 2). Seven patients (13%)
were not evaluated due to lack of follow-up data. Of the remaining 45 patients, 35 patients
(78%) responded to the drug. Treatment was discontinued in 8 (23%) of the responding
patients due to adverse reactions [33, 34]. None of the patients treated with romiplostim
entered sustained remission. A total of 10 patients (22%) did not respond to romiplostim.
Eltrombopag was used in 64 patients (16%; Table 1). One patient (2%) was not evaluated due
to lack of follow-up data. Of the remaining 63 patients, 45 patients (71%) responded to treat-
ment (Table 2). Four of these patients (9%) entered sustained remission. Fourteen (31%) of the
45 responding patients discontinued treatment due to intolerable adverse reactions [33, 34].
Eighteen patients (29%) did not rspond to eltrombopag.
IVIG was used in 133 patients (33%) on at least one occasion (Table 1). Seven patients (5%)
were not evaluated due to lack of follow-up data. Of the remaining 126 patients, 94 (75%)
responded to treatment, and none of the responding patients developed intolerable adverse
reactions that contraindicated a re-treatment with IVIG. The observed adverse reactions were
usually mild and related to headaches and rarely allergic reactions. Interestingly, four patients
(4%) entered sustained remission following IVIG treatment (Table 1). Thirty-two patients
(25%) did not respond to IVIG.
Therapy with anti-D was selectively used in 54 Rh(D)-positive patients (14%) with refrac-
tory ITP (Table 1). Two patients (4%) were not evaluated due to lack of follow-up data. Never-
theless, of the remaining 52 patients, 19 (37%) responded to anti-D and two patients (4%) had
adverse reactions (nausea, fever, headache) 24 h after administration that may be attributed to
other origins. Hemolysis was not observed in a single patient. The lack of hemolysis might be
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explained by the subcutaneous administration [35–38]. Thirty-three patients (63%) did not
respond to anti-D.
Splx was performed in 20 patients (5%) prior to consultation at our institute. Of the remain-
ing 380 non-splenectomized patients, 26 (7%) underwent Splx during the observation period
(Table 1). One patient (1%) was not evaluated due to lack of follow-up data. Of the remaining
25 patients, 15 (60%) patients entered sustained remission after Splx. One non-responding
patient developed postoperative abdominal pain and was diagnosed portal vein thrombosis
(Table 1).
Discussion
The present study mainly focused on the efficacy and tolerability of each drug used in practice
in the treatment of ITP rather than on patient outcome. While the latter question has been
acknowledged by several studies [39–42], the former question has not yet been adequately
addressed. The results presented in this study are based on patients treated by one physician
who treats ITP patients since the 1980, not only on the basis of general recommendations, but
also under individual consideration of each patient’s conditions. These included prior therapy,
bleeding risk, plc, gender, age, weight, comorbidity, quality of life and patient’s preference. The
importance of the latter point is reflected by the fact that many patients are well-informed on
ITP. Based on the aforementioned criteria, at least 25% of patients did not require any treatment
during observation (Fig 2). These patients did not have any significant bleeding or bleeding risk
due to comorbidities, menstruation, activities/sports associated to injuries or invasive medical
interventions. Their plc remained at levels compensating primary hemostasis ( 30 x 109/L)
during observation. This observation is in agreement with previously published data [23].
Drug-induced thrombocytopenia rather than ITP was suspected in 24 patients. At least
nine of these patients (38%) entered sustained remission following discontinuation of the sus-
pected drug.
Unfortunately, many patients (55%) received steroids prior to consultation at our institute,
even in cases where steroids should have been avoided, e.g., in patients with obesity, diabetes,
and/or hypertension. Based on the aforementioned criteria, treatment with steroids was pre-
ferred as first-line therapy in only 31 of 143 patients that had not been treated for ITP prior to
admission in our institute. Of these selected patients, 20 (65%) showed long-term beneficial
effects that may have been solely attributed to steroids. However, these patients were a selected
group of uncomplicated cases, e.g. young individuals with few or no comorbidities, with mild
rather than severe ITP, no recognizable contraindication for treatment with steroids, and
appeared to have a relatively low risk of developing intolerance. As the majority of such
selected patients appeared to respond to steroids, we believe that this supports the notion of
retaining steroids as a first-line therapy in ITP, however only in selected patients. In compari-
son, only (12%) of pretreated patients (27/257), still remained under steroid treatment upon
initial presentation at our institute (Fig 1), and this treatment was discontinued in six of these
cases during observation. Therefor the number of patients that continued treatment (10%) is
primarily in agreement with previous reports [4].
Anti-D was selectively used in 54 Rh(D)-positive patients with severe ITP that were largely
refractory to previous medical therapy (Table 1). This may explain the relatively low response
rate (37%) compared to unselected patient cohorts [4]. The reason for anti-D being not used
in uncomplicated (naïve) patients is related to the fact that this therapeutic option is still not
licensed for treatment of ITP in Germany.
Prior to admission, 20 patients (5%) of the patient cohort were already splenectomized and
four of them did not require any further medication. The other 16 patients required further
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therapy. During observation, only 26 (11%) of the remaining 284 non splenectomized and
treated patients remained refractory to all available drugs, and ultimately underwent Splx. Fif-
teen of these patients (60%) entered sustained remission, and 10 (40%) required further treat-
ments (Table 1). Of these 10 patients, seven patients responded to treatment with TPO-RA
(six patients to romiplostim, one patient to eltrombopag), and the remaining patient
responded to azathioprine and prednisolone ( 7,5 mg/d). Altogether, the therapies used in 26
splenectomized patients who required further therapy, were more effective than that used
prior to Splx (Table 3).
The finding that most therapeutic options were observed to become effective after Splx con-
tinues to emphasize the role of this therapeutic measure in the management of ITP as long as
there is no specific treatment available. A similar conclusion has been drawn in previous stud-
ies [43, 44]. Most intriguingly, the efficacy of splenectomy appears to be independent of previ-
ous therapies and may therefore be considered as the ultima ratio therapy in refractory
patients. Only two of the treated patients in this study remained refractory to all drugs used,
even after splenectomy. One of these, a 53 year old female, who remained refractory to all
drugs used (high-dose IVIG, platelet transfusion, eltrombopag, romiplostim, dexamethasone,
dapsone and ultimately myeloablative dose cyclophosphamide 4 x 50 mg/kg/d) post-splenec-
tomy. At first admission her blood count revealed only isolated thrombocytopenia and the
blood marrow smear and bone marrow aspiration showed no abnormalities. This patient
developed acute myeloid leukemia and died several weeks following treatment. The second
refractory patient remained at risk of bleeding.
The results obtained using immunosuppressive agents were similar to those reported in
previous studies [4]. Interestingly, similar response rates were observed in patients treated
with azathioprine and treated with both azathioprine and low-dose (1–7.5 mg/d) prednisolone
Table 3. Therapies prior to and after splenectomy.
Total number of splenectomized patients (n = 46) Patients receiving treatment after Splx (n = 26)
Abortive therapies prior to Splx Patients (n) Therapies after Splx Patients (n) Response Non-R
Pred 42 Prednisolone 5 3 (60%) 2 (40%)
IVIG 28 IVIG 12 9 (75%) 3 (25%)
Dexa 9 Dexa 2 1 (50%) 1 (50%)
Anti-D 12 Anti-D 1 - 1 (100%)
Romip 6 Romip 13 10 (77%) 3 (33%)
Eltromb 7 Eltromb 8 4 (50%) 4 (50%)
Rituxi 4 Rituxi 2 - 2 (100%)
Aza + Pred 5 Aza + Pred 6 2 (33%) 6 (66%)
Aza 4 Aza 1 1 (100%) -
Cycl 5 Cycl (+Preda) 2 1 (50%) 1 (50%)
Ciclo 3 Ciclo 1 1 (50%) -
MMF 4 MMF (+Predb) 2 - 2 (100%)
Dapsone 1 Dapsone - - -
Response = short-course treatments: elevation of platelets 30 x109/L and at least doubling of the baseline value within their known agent specific time to peak
response [32]. Continuous treatments: sustained platelet counts30 x109/L with at least doubling the baseline value and absence of bleeding during observation.
Non-R = non-responder (patients that did not show elevation of platelets 30 x109/L and at least doubling of the baseline value).
Aza = azathioprine, Ciclo = ciclosporin, Cycl = cyclophosphamide, Dexa = dexamethasone, Eltromb = eltrombopag, IVIG = intravenous immunoglobulin,
MMF = mycophenolate- mofetil, MTX = methotrexate, Pred = prednisolone, Romip = romiplostim, Rituxi = rituximab, Splx = splenectomy.
a One patient with concomitant prednisolone therapy;
b one patient with concomitant prednisolone therapy.
https://doi.org/10.1371/journal.pone.0198184.t003
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(50% vs. 51%). Other immunosuppressive drugs including cyclophosphamide, ciclosporin and
mycophenolate-mofetil were only used in refractory patients. In most cases, the combination
treatment of steroids and other immunosuppressive drugs was required to reduce steroid
doses. A small group of 5 patients suffering from rheumatic diseases (3 patients with rheuma-
toid arthritis, 1 patient with systemic lupus erythematodes, 1 patient with psoriasis arthritis)
was treated with MTX. None of these patients has been treated with MTX because of ITP. Nev-
ertheless, a therapeutic effect of MTX on ITP, cannot be excluded. Two patients with concomi-
tant prednisolone therapy met the response criteria during this therapy (Table 2).
IVIG was administered to 133 patients, with 94 patients (75%) responding to treatment
(Table 3). Thirty-two patients (25%) did not show an increase in plc as defined by the response
criteria. In patients with bleeding, bleeding did not progress or was stopped after IVIG admin-
istration. We recently demonstrated that high dose IVIG may stop bleeding within 12 h after
administration, independent of plc [45]. This phenomenon might be explained by an
increased consumption of platelets for normalization of decompensated primary hemostasis
in treated patients.
The TPO-RA, romiplostim and eltrombopag are increasingly used in the treatment of ITP.
Previous studies have shown both drugs to be generally effective and safe in most ITP patients
[9–12, 33, 34, 46–48]. However, in some cases, severe or dangerous adverse reactions including
thromboembolic events, arthralgia, increased bone marrow fibrosis and myeloproliferative
neoplasias may occur [9–12, 33, 34, 46–48]. Our results indicate that TPO-RAs are less effec-
tive and less tolerated (49–59%) than previously reported and may potentially result in an
increased number of adverse reactions than previously reported [9–12, 33, 34, 46–48]. Adverse
reactions occurred in 33% (romiplostim) and 35% (eltrombopag) of patients, respectively. Of
the responding patients, eight (23%) discontinued romiplostim, and 14 (31%) discontinued
eltrombopag due to intolerable adverse reactions. Nevertheless, these drugs have not only
changed therapeutic treatment options in ITP, but also the outcome of treated patients. Previ-
ous studies have shown that approximately one-third of patients remained refractory to con-
ventional treatment [49]. Currently, approximately <10% of patients may remain refractory to
treatment [50, 51] and death may occur only in isolated cases [52]. In addition, the use of
immunosuppressive drugs can nowadays rarely be justified.
Finally, independent of Splx, 18 patients (6%) entered sustained remission (plc100 x 109/
L) due to treatment with various drugs (Tables 1 and 2). It remains unknown whether this phe-
nomenon can only be attributed to the applied drugs mentioned in this study.
Conclusions
Although only isolated patients may remain refractory to the currently available treatment
options in ITP, there are many aspects that remain evident for the need of alternative drugs
including specificity, safety, efficacy, predictability, and costs. In addition, we and others [13,
14, 27] agree with guidelines as a source of basic information, but individualized treatment is
needed in many cases.
Limitations of study
As the Dataset, collected retrospectively, does not contain uniquely all parameters for each
patient, we prefered to conduct only descriptive instead of inferential statistics. Our retrospec-
tive study represents the treatment results in clinical practice. Thus, there was no possibility of
monitoring platelet counts at prespecified standardized moments as in prospective trials.
Moreover, the time to response is variable and cannot be predicted. It must be emphasized
that not all adverse reactions were excluded, e.g. bone marrow fibrosis. In addition, a systemic
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screening for portal vein thrombosis by ultrasound or CT-scan after Splx was not performed.
Furthermore our study presents data collected over a period of 20 years. During this period,
therapeutic options as well as treatment recommendations have changed.
Initially, most patients appeared to have isolated ITP. During observation, at least 57%
(n = 227) of our patients exhibited other abnormalities e.g., DAT positivity, antibody defi-
ciency, malignancies, or other diseases and abnormalities, Based on our experiences [53], the
common classification into a primary and a secondary disease is not certain and variable in
many cases. Moreover, the ITP itself might be responsible for the development of associated
diseases at least in some cases. This is confirmed by the matter of fact that the manifestation of
ITP precedes the manifestation of the associated diseases in some patients. Thus the question
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